|
Hosted by |
|
 |
|
 |
|
Sponsors |
|
 |
|
 |
|
 |
|
Exhibitors |
|
 |
|
 |
|
For
sponsorship information, send an email to
matt@maavc.com. |
|
April
26, 2006 Conference Speaker Profiles
Risdall Conference
Center
550 Main Street, New Brighton, MN 55112
| |
April 26, 2006
Speaker Profiles |
|
 |
|
Gary Anderson, CEO,
Netbriefings (MN)
-
The opportunity in
the overall web conferencing market is immense. Netbriefings has
been a player in this market since 2000. It knows the market and
has a solid foothold as a preferred vendor. The Company has
developed proprietary software tools. It plays in both the
collaborative and broadcast segments, but differentiates at the
high end with large, broadcast-style webcasts where profit margins
are more attractive. |
 |
|
Netbriefings
has an impressive list of repetitive customers, such as AOL,
Ecolab, Lawson Software, Navigation Technologies, Ohio
National and Sopheon. The Company’s financials are strong.
Revenues have been increasing right along with the web
conferencing market. Netbriefings has been cash flow positive
since 2004 and continues to be profitable. The Company’s
strategy to take advantage of this market opportunity involves
select acquisitions of smaller teleconference firms that do
not have the full suite of offerings in the web conferencing
arena to service their customer base. By acquiring these
companies, Netbriefings drives rapid revenue growth and has a
larger customer base to resell its high-end, large broadcast
style webcasting services. It also increases the value of the
teleconference revenue, since those firms have a multiplier of
.5 to 1 times their revenue while web conferencing firms
serving Netbriefings’ market have a multiplier of 3 to 5 times
or more their revenue. |
|
|
 |
|
Greg Backlund,
CEO, SuperProtection (MN)
- SuperProtection,
Inc. (SPI) is poised for rapid growth by defining and dominating
specialty retail markets using breakthrough proprietary
technology. SPI has secured a North American exclusive
license for the use of patented SuperFabric® brand material in
large consumer markets, with immediate opportunities to expand
into additional national and global segments. |
 |
|
SPI’s comfortable, washable,
high-tech SafeGrasp® brand gloves and other apparel protect
users from many types of hazards, and they have earned an
enthusiastic customer following and numerous product
recognition awards and recommendations. They offer
protection, durability, comfort and rugged good looks
unmatched by any other existing products. SPI has established
rapidly growing sales in this market. The company also markets
lines of high-performance designer cleaning pads and cloths
made with SuperFabric® technology. SPI expects to build
to over $20,000,000 in annual revenues by 2011, and plans to
reach profitability in 2007. With additional national and
global expansions, $50,000,000 in revenue is readily
attainable. SPI has already established sales with over 500
retail stores, selling directly or through distributors
including Amazon.com, Ace Hardware, True Value Hardware, and
SuperValu. The Chairman of Sharper Image recently contacted
SPI to request samples, and the major U.S. retail chains will
approached next. An experienced management and advisory
team is in place, led by Chairman Rick Jahnke, former CEO of
CNS Breathe Rite. The exit strategy is a sale to a larger
consumer-products company within three to seven years. SPI
will raise $2,500,000 over the next two years to fund the
rapid growth phase. |
|
|
 |
|
John Biondi, COO,
Lucigen (WI)
- Lucigen
Corporation is in the business of discovering and
commercializing high-value enzymes for biofuels by utilizing
the power of its proprietary technical platform to selectively
mine novel microbes from previously uncloned, and therefore,
untapped genetic material. |
 |
|
The Company’s competitive
advantage comes from its unique ability to clone genes and
entire genomes previously considered to be unclonable and to
do so from as little as one cell. Lucigen has been applying
this technology to access the genomes of rare microbes for
novel, high performance enzymes that have selected attributes
ideal for improving the production of ethanol from a variety
of feedstocks. Lucigen is developing a series of enzymes
projected to improve the efficiency of corn ethanol production
between 10-15% with no additional requirements for plant or
equipment. Also as part of its biofuels initiative, Lucigen
is developing enzymes that will, for the first time, convert
soy meal carbohydrate to ethanol while leaving the valuable
soy protein undisturbed. |
|
|
 |
|
Brian Gramer,
CEO,
Vtrenz (ND)
- Vtrenz is
the industry leader in on-demand marketing automation software.
Built specifically for the marketing professional, Vtrenz
iMarketing Automation makes it easy to analyze, plan, build,
execute and measure your complete marketing portfolio - all
without the IT bottleneck. |
 |
|
More powerful than email marketing
and a better ROI than CRM, Vtrenz provides superior marketing
results. |
|
|
 |
|
John Griffin,
CEO,
Gruby Technologies (MN/ND)
- Gruby
Technologies Inc., a privately-held, emerging-growth Company, is
the leader in on-demand real-time locating solutions for
healthcare. |
 |
|
Gruby
Technologies’ C-Freedom software delivers real-time location,
collaborative, and business intelligence applications designed
with specific healthcare environments in mind. These
on-demand applications deliver returns on investment within
one year by improving utilization of assets, staff
productivity, patient and staff safety, and patient
satisfaction. Gruby Technologies' vision is to be the leader
in utilizing real-time information to deliver dramatic
improvements in staff productivity, patient safety, and
operational cost savings. |
|
|
 |
|
Tom Ingolia, CEO,
Medisyn Technologies (MN)
- Medisyn is a
biotechnology company with recently proven technology with
exceptional promise. The technology, a lead identification
modeling capability based on novel mathematical topology-based
programs, is ready for application and needs no further
development. |
 |
|
Recent proof-of-concept studies
with several different partners have produced extraordinary
results, with novel lead compounds discovered in each case.
Examination of the technology by several experts has led to
the unanimous conclusion that the technology is unique,
well-grounded, and has outstanding potential. In order
to exploit the technology, Medisyn is seeking funds to create
a portfolio of drug candidates. Because the methods are
efficient and inexpensive, Medisyn can create a valuable
portfolio of pre-clinical-stage leads without incurring high
expenses or overhead. |
|
|
 |
|
|
 |
|
Michael Murphy,
VP,
Bancmetrics (MN)
-
Bancmetrics provides Internet-based software tools
for fixed-income brokers and dealers. The core product is the
Bancmetrics portfolio accounting system that was started in July
2002 as a division of a banking software enterprise. |
 |
|
The company was purchased in 2003 by COR-IBS, Inc.
a software developer focusing on financial institutions.
The current management team purchased the company from COR-IBS
in January of 2005. Portfolio Analysis Systems, Inc.
achieved profitability in the first quarter after that
acquisition.
The Company currently has alliances with 13 broker dealers
throughout the United States and Canada, processing over 100
investment portfolios for financial institutions. Bancmetrics
has achieved a 37% annual revenue growth since the management
repurchase. With Bancmetrics client base representing the
banking industry (53%), thrift industry (11%) and credit
unions (27%), the company has met the initial goal of
establishing its presence within the financial institution
market place. Bancmetrics is embarking upon the next
step of its business plan, the development of a suite of
products designed to focus on fixed income analysis and sales
support designed for the small to mid-sized broker dealer
market. Being one of the few independent third party portfolio
accounting services available to the financial institution
market, Bancmetrics feels that it is in a unique position to
leverage off its established client base to expand and
penetrate deeper into the target market. |
|
|
 |
|
Dale Nugent, CEO,
RivaTek (MN)
- RivaTek is a
technology company solving emerging process control equipment
needs. The company has developed, and patented a core technology
with significant benefits to processing companies across a wide
variety of applications, including: biotechnology, food
processing, specialty chemicals, pharmaceutical manufacturing and
semiconductor fabrication. |
 |
|
RivaTek’s
first product using this technology – the VFC-370™ – delivers
pressure, temperature and flow measurements, and controls the
flow rate of critical process liquids. It is an enhancement to
the differential pressure flow measurement technique - the
leading methodology applied for the most frequently controlled
variable in process settings. RivaTek’s experienced
management is backed by a strong team of directors and
advisors. The company has achieved first revenues and has a
rapidly expanding sales pipeline including key semiconductor
equipment manufacturers, as well as chip fabricators.
RivaTek’s mission is to continue to develop innovative process
control technologies, leading to products with high potential
for growth and value across a diversified industry base. |
|
|
 |
|
Richard Rotondo, CEO,
Mediscovery (MN)
- Mediscovery has the
highest productivity to expense ratio in the pharmaceutical
Industry. In little over three years, and with less than $200,000,
Mediscovery has developed two anticancer medicines, Cancure™ and
Cancurol™. |
 |
|
Both medicines have been validated
by the US National Cancer Institute as having activity against
all types of cancer – thereby reducing its comprehensive
developmental costs. These anticancer medicines are perceived
to have the highest therapeutic index possible. Mediscovery is
now focusing on accelerating human clinical studies for these
two anticancer medicines, Cancure™ and Cancurol™. In one
month, Mediscovery has identified a series of anti-influenza
medicines. One of which is expected to be approved within a
year because of its lack of toxicities. Mediscovery has also
reached terms to license its anti bird flu vaccine, Med-vac™
to a major veterinary products supplier. Mediscovery is
a pharmaceutical engineering company that is moving forward
with a unique and proprietary fourth generation software
technology that has been validated internationally as being
the most accurate pharmaceutical engineering software
technology in the world. This proprietary technology is based
on state of the art mathematical topology-based programs
developed independently at the University of Spain, Valencia.
Mediscovery has recently reached terms to license the
exclusive rights to this unique fourth generation software
technology. Peer-reviewed, proof-of-concept, laboratory
validated studies have produced extraordinary results, with
novel lead compounds discovered in each case for a wide
variety of diseases from cancer, to tuberculosis, to malaria,
to HIV (AIDS). And with nearly sixty peer-reviewed, published
in less than four years, has led to the unanimous conclusion
among established experts that the Mediscovery technology is
unique and is superior to all other pharmaceutical engineering
software technologies. Mediscovery has created a valuable
portfolio of nearly twenty pre-clinical-stage leads. |
|
|
